Update on lipid-lowering therapy and LDL-cholesterol targets
作者： Stephen D Wiviott , Christopher P Cannon
关键词:
摘要: Serum cholesterol has long been recognized as an important risk factor for the development and progression of atherosclerotic vascular disease. For more than 30 years, improved outcomes with lipid lowering have demonstrated. As a result these data, National Heart, Lung, Blood Institute (NHLBI) convened Cholesterol Education Program-Adult Treatment Panel I (NCEP ATP I). This panel similar ones around world served to set standards in clinical practice. Subsequent revisions II III) led greater focus being placed on LDL, targets LDL levels based patients' subsequent coronary disease events. Since publication NCEP III guidelines, several large-scale trials conducted, findings which potential impact practice standards. In this article we current guidelines lipid-lowering therapy, review results implications completed trials, consider utility additional preventive such C-reactive protein HDL. We also prospects treatments future goals.
nature.com
sci-hub.se 参考文章(58)
Steven E. Nissen, Taro Tsunoda, E. Murat Tuzcu, Paul Schoenhagen, Christopher J. Cooper, Muhammad Yasin, Gregory M. Eaton, Michael A. Lauer, W. Scott Sheldon, Cindy L. Grines, Stephen Halpern, Tim Crowe, James C. Blankenship, Richard Kerensky, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. ,vol. 290, pp. 2292- 2300 ,(2003) , 10.1001/JAMA.290.17.2292
J. Tuomilehto, G. Vidgren, L. Toivanen, E. Tuomilehto-Wolf, K. Kohtamaki, J. Stengård, P. Zimmet, I.R. Mackay, Mj Rowley, P. Koskela, Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. The Lancet. ,vol. 343, pp. 1383- 1385 ,(1994) , 10.1016/S0140-6736(94)92521-6
Terje R Pedersen, Ole Faergeman, John JP Kastelein, Anders G Olsson, Matti J Tikkanen, Ingar Holme, Mogens Lytken Larsen, Fredrik S Bendiksen, Christina Lindahl, Michael Szarek, John Tsai, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group, High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial InfarctionThe IDEAL Study: A Randomized Controlled Trial JAMA. ,vol. 294, pp. 2437- 2445 ,(2005) , 10.1001/JAMA.294.19.2437
Steven E. Nissen, E. Murat Tuzcu, Paul Schoenhagen, Tim Crowe, William J. Sasiela, John Tsai, John Orazem, Raymond D. Magorien, Charles O'Shaughnessy, Peter Ganz, Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease The New England Journal of Medicine. ,vol. 352, pp. 29- 38 ,(2005) , 10.1056/NEJMOA042000
Guy De Backer, Ettore Ambrosioni, Knut Borch-Johnsen, Carlos Brotons, Renata Cifkova, Jean Dallongeville, Shah Ebrahim, Ole Faergeman, Ian Graham, Giuseppe Mancia, Volkert Manger Cats, Kristina Orth-Gomér, Joep Perk, Kalevi Pyorälä, José L Rodicio, Susana Sans, Vedat Sansoy, Udo Sechtem, Sigmund Silber, Troels Thomsene, David Wood, European Atherosclerosis Society EAS, European Heart Network EHN, European Association for the Study of Diabetes (EASD, European Society of Hypertension, European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis. ,vol. 173, pp. 379- 389 ,(2004) , 10.1016/J.ATHEROSCLEROSIS.2004.02.013
Scott M Grundy, James I Cleeman, C Noel Bairey Merz, H Bryan Brewer Jr, Luther T Clark, Donald B Hunninghake, Richard C Pasternak, Sidney C Smith Jr, Neil J Stone, None, Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation. ,vol. 44, pp. 227- 239 ,(2004) , 10.1161/01.CIR.0000133317.49796.0E
Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I Mackness, Valentine Charlton-Menys, John H Fuller, CARDS investigators, None, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial The Lancet. ,vol. 364, pp. 685- 696 ,(2004) , 10.1016/S0140-6736(04)16895-5
Eva S Istvan, Johann Deisenhofer, Structural Mechanism for Statin Inhibition of HMG-CoA Reductase Science. ,vol. 292, pp. 1160- 1164 ,(2001) , 10.1126/SCIENCE.1059344
, Richard C. Pasternak, Sidney C. Smith, C. Noel Bairey-Merz, Scott M. Grundy, James I. Cleeman, Claude Lenfant, ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Stroke. ,vol. 33, pp. 2337- 2341 ,(2002) , 10.1161/01.STR.0000034125.94759.41
Paul L Canner, Kenneth G Berge, Nanette K Wenger, Jeremiah Stamler, Lawrence Friedman, Ronald J Prineas, William Friedewald, Coronary Drug Project Research Group, None, Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin Journal of the American College of Cardiology. ,vol. 8, pp. 1245- 1255 ,(1986) , 10.1016/S0735-1097(86)80293-5